Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.

Fiche publication

Date publication

mai 2024

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Pr LEPAGE Côme

Tous les auteurs :
Boisteau E, Dahan L, Williet N, Le Malicot K, Desramé J, Bouché O, Petorin C, Malka D, Rebischung C, Aparicio T, Lecaille C, Rinaldi Y, Turpin A, Bignon AL, Bachet JB, Lepage C, Granger V, Legoux JL, Deplanque G, Baconnier M, Lecomte T, Bonnet I, Seitz JF, François E, Lièvre A,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39235326

Résumé

Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this strategy.